4Ds Memory Limited

4DS

4DS Memory Ltd. operates as a semiconductor development company. The company is headquartered in Perth, Western Australia. The company went IPO on 2010-12-09. The firm is engaged in the development of a non-volatile memory technology, pioneering Interface Switching resistive random-access memory (ReRAM) for gigabyte storage in mobile and cloud. Interface Switching ReRAM, an area-based ReRAM technology positioned for Storage Class Memory in mobile devices and cloud data centers. The company owns a patented Internet protocol (IP) portfolio, comprising 34 United States patents granted, which has been developed in-house to create high-density storage class memory. The 4DS Interface Switching ReRAM meets the essential requirements for Storage Class Memory close to DRAM. The firm also collaborates with imec, a research and hub in nanoelectronics and digital technologies.

Aeon Metals Limited

AML

Aeon Metals Ltd. engages in the exploration of copper and molybdenum properties. The company is headquartered in Gold Coast, Queensland. The company went IPO on 2007-06-14. The firm holds a 100% ownership interest in the Walford Creek Copper-Cobalt Project (Walford Creek Project), which is located in north-west Queensland, approximately 340 kilometers (km) to the north north-west of Mt Isa. The company also has interests in various exploration permits in Northwest Queensland. This tenement package covers approximately 1,441 square kilometers (km2) and located in the Mount Isa minerals province in northwest Queensland. The Southeast Queensland tenement package lies approximately 30 km west of the town of Monto, Queensland. These permits extend approximately 500 km from north to south and are subdivided into four main project areas, Constance Range, Isa North, Isa West, and Isa South. The company includes contiguous land holding, approximately 170 km, along the Mt Isa Fault, bordering north and south of Glencore Xstrata’s Mount Isa Mines.

Brainchip Holdings Ltd

BRN

BrainChip Holdings Ltd. engages in the development of software and hardware solutions for artificial intelligence and machine learning applications. The company is headquartered in Sydney, New South Wales and currently employs 78 full-time employees. The company went IPO on 2011-11-09. The Company’s software and hardware accelerated solutions for advanced AI and machine learning applications with a primary focus on the development of its Akida Neuromorphic Processor. The Company’s fully digital, event-based AI processor, Akida, uses neuromorphic principles to mimic the human brain, analyzing only essential sensor inputs at the point of acquisition, processing data with unparalleled efficiency, precision, and economy of energy. Akida enables Edge learning local to the chip, independent of the cloud, reducing latency while improving privacy and data security. Its other products include MetaTF, 2nd Generation akida, Akida1000 reference chip and Akida Enablement Platforms. Akida Enablement Platforms include Akida PCIe Board, Akida Development Kit Shuttle PC, and Akida Development Kit Raspberry Pi.

Carbonxt Group Limited

CG1

Carbonxt Group Ltd. engages in the development and marketing of activated carbon products. The company is headquartered in Gainesville Florida, Florida. The company went IPO on 2018-01-23. The firm is engaged in the development and sale of specialized Activated Carbon (AC) products, including Powdered Activated Carbon (PAC) and AC pellets for the removal of pollutants and toxins in industrial processes. Its products are used in industrial air purification, wastewater treatment and other liquid and gas phase markets, primarily for the capture of mercury and sulfur in order to reduce harmful emissions into the atmosphere. Its products include MATS-PAC, MATS-PACK S, CXT-WETJECT, CXT-NAQ-ACP, CEM-PAC, CEM-PAC-S, MACT-PAC, CXT-BB500, CXT-BB600, CXT-BB800, CXT-BB+, CXT-ACP60V, CXT-ACP50V, CXT-ACP45V, CXT-AQP50 and HYDRESTOR. The Company’s products application includes nutrient recovery technology, coal-fired power plants, cement plants, waste to energy: industrial boilers and incinerators, potable water, and volatile organic compounds (VOC) and contaminant removal.

Noxopharm Limited

NOX

Noxopharm Ltd. engages in the research and development of drugs. The company is headquartered in Castle Hill, New South Wales and currently employs 1,000 full-time employees. The company went IPO on 2016-08-09. The company is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. The company utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.